Page 139 - Genentech News Today

The U.S. Food and Drug Administration had granted accelerated approval to Gavreto in 2020 for treating patients aged 12 years and above with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy. Blueprint said Genentech decided not to pursue the late-stage study required to confirm the drug's benefits due to feasibility after consultation with the FDA. Genentech previously said the use of the drug in the indication accounts for a fraction of its overall ...

Data from ongoing FIREFISH study confirm long-term efficacy and safety profile of Evrysdi in children with Type 1 SMANinety-one percent of children were alive at month 48More than 95% maintained the...

The US indication for pralsetinib in the treatment of adult and pediatric patients aged 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy has been voluntarily withdrawn by Genentech.

A new analysis revealed that end-of-life systemic treatment rates were associated with a patients race, insurance type, and practice setting.

Experts assess the potential of colchicine 0.5 mg to treat residual risk for atherosclerotic cardiovascular disease (ASCVD) in patients with immune-mediated inflammatory diseases (IMIDs).

Investigators found that the first biosimilar of trastuzumab, trastuzumab-anns (Kanjinti; Amgen), did maintain a strong and persistent advantage over the other 4 biosimilar entrants.

 Initiation of pivotal Phase 3 trial in non-small cell lung cancer (NSCLC) marks the first landmark in BioNTech’s and OncoC4’s strategic collaboration initiated in March 2023 with the aim to evaluate BNT316/ONC-392 in various solid tumor ...

Companies are beginning to expand health benefits to cover menopause as Millennials start to enter perimenopause.

I wonder what to write and if Ill want to anymore. One of the things, very hard to do, is to create something when you feel youre using both hands to ...

Healthcare has a lot to gain from a more equitable approach.